A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts

BACKGROUND: Between 30 and 40% of human breast cancers express a defective tumor suppressor p53 gene. Wild-type p53 tumor suppressor protein promotes cell-cycle arrest and apoptosis and inhibits vascular endothelial growth factor–dependent angiogenesis, whereas mutant p53 protein (mtp53) lacks these...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yayun, Mafuvadze, Benford, Besch-Williford, Cynthia, Hyder, Salman M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868596/
https://www.ncbi.nlm.nih.gov/pubmed/29606888
http://dx.doi.org/10.2147/BCTT.S156285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868596/
https://www.ncbi.nlm.nih.gov/pubmed/29606888
http://dx.doi.org/10.2147/BCTT.S156285

Ejemplares similares